Polar Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Polar Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$53.2M	Sell	95,000 -64,440	-40%	-$39.1M	0.39%	75
2020 Q2	$99.4M	Buy	159,440 +109,440	+219%	+$62.1M	0.86%	25
2020 Q1	$24.4M	Sell	50,000 -45,223	-47%	-$18.7M	0.26%	113
2019 Q4	$35.8M	Sell	95,223 -4,777	-5%	-$1.61M	0.31%	108
2019 Q3	$27.7M	Hold	100,000	–	–	0.25%	118
2019 Q2	$31.3M	Sell	100,000 -12,989	-11%	-$4.32M	0.27%	117
2019 Q1	$46.4M	Buy	112,989 +32,989	+41%	+$13.6M	0.43%	80
2018 Q4	$29.9M	Buy	80,000 +15,000	+23%	+$5.49M	0.32%	107
2018 Q3	$26.3M	Buy	65,000 +25,000	+63%	+$9.51M	0.22%	132
2018 Q2	$13.8K	Buy	40,000 +2,500	+7%	+$782K	0.08%	175
2018 Q1	$12.9M	Sell	37,500 -2,500	-6%	-$870K	0.13%	168
2017 Q4	$15M	Buy	40,000 +22,500	+129%	+$9.11M	0.16%	150
2017 Q3	$7.83M	Sell	17,500 -81,263	-82%	-$38.7M	0.09%	180
2017 Q2	$48.5M	Buy	98,763 +70,763	+253%	+$31M	0.65%	47
2017 Q1	$10.8M	Sell	28,000 -3,250	-10%	-$1.2M	0.16%	138
2016 Q4	$11.5M	Buy	31,250 +18,700	+149%	+$7.11M	0.18%	144
2016 Q3	$5.04M	Sell	12,550 -1,359	-10%	-$545K	0.09%	181
2016 Q2	$4.86M	Buy	13,909 +4,862	+54%	+$1.87M	0.09%	180
2016 Q1	$3.26M	Sell	9,047 -55,031	-86%	-$22.7M	0.06%	196
2015 Q4	$34.8M	Buy	64,078 +2,001	+3%	+$1.08M	0.63%	50
2015 Q3	$28.9M	Buy	62,077 +56,084	+936%	+$30.1M	0.58%	48
2015 Q2	$3.06M	Buy	5,993 +71	+1%	+$34.6K	0.06%	207
2015 Q1	$2.67M	Buy	5,922 +1,976	+50%	+$837K	0.05%	208
2014 Q4	$1.62M	Sell	3,946 -56,291	-93%	-$22.1M	0.03%	221
2014 Q3	$21.7M	Buy	+60,237	New	+$20.2M	0.46%	69
2014 Q2	–	Sell	-1,591	Closed	-$478K	–	283
2014 Q1	$478K	Sell	1,591 -74,493	-98%	-$23M	0.01%	251
2013 Q4	$20.9M	Buy	76,084 +24,084	+46%	+$6.93M	0.5%	63
2013 Q3	$16.3K	Buy	52,000 +5,000	+11%	+$1.32M	0.43%	75
2013 Q2	$10.6M	Buy	+47,000	New	+$10.9M	0.37%	112

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Polar Capital's REGN Position: Q3 2020 in Review

Polar Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 40% in Q3 2020, selling an estimated $39.1M and leaving 95,000 shares worth $53.2M. The position accounts for 0.39% of the portfolio, ranked #75.

Polar Capital first reported a position in REGN in Q2 2013 and has held it in 29 quarters since. The position peaked at $99.4M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

Polar Capital held 95,000 shares of Regeneron Pharmaceuticals worth $53.2M as of Q3 2020.
Polar Capital sold 64,440 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $39.1M.
Regeneron Pharmaceuticals made up 0.39% of Polar Capital's portfolio in Q3 2020, its #75 holding.
Polar Capital first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
Polar Capital's Regeneron Pharmaceuticals position peaked at $99.4M in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.